Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

@article{Nakamura2009LurasidoneIT,
  title={Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.},
  author={Mitsutaka Nakamura and Masaaki Ogasa and John R. Guarino and Debra Phillips and Joseph M. Severs and Josephine B. Cucchiaro and Antony D. Loebel},
  journal={The Journal of clinical psychiatry},
  year={2009},
  volume={70 6},
  pages={829-36}
}
OBJECTIVE Lurasidone is a novel psychotropic agent with high affinity for D(2) and 5-HT(2A) receptors, as well as for receptors implicated in the enhancement of cognition and mood and the reduction of negative symptoms (5-HT(7), 5-HT(1A), and alpha(2c)). The objective of the study was to evaluate the safety and efficacy of lurasidone in patients hospitalized for an acute exacerbation of DSM-IV-defined schizophrenia. METHOD Patients were randomly assigned to 6 weeks of double-blind treatment… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry • 2012
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…